Suffolk Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Suffolk Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-314,993	Closed	-$1.08M	–	133
2016 Q3	$1.08M	Sell	314,993 -126,922	-29%	-$496K	0.15%	121
2016 Q2	$1.54M	Buy	441,915 +31,023	+8%	+$131K	0.2%	127
2016 Q1	$1.7M	Buy	410,892 +48,995	+14%	+$175K	0.23%	121
2015 Q4	$1.61M	Buy	361,897 +128,803	+55%	+$706K	0.2%	128
2015 Q3	$1.42M	Buy	233,094 +25,677	+12%	+$228K	0.19%	123
2015 Q2	$2.46M	Buy	207,417 +89,317	+76%	+$1.36M	0.29%	111
2015 Q1	$2.06M	Buy	+118,100	New	+$2.42M	0.24%	121

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Suffolk Capital Management's ABUS Position: Q4 2016 in Review

Suffolk Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2016, closing a stake of 314,993 shares — an estimated $1.08M sold.

Suffolk Capital Management first reported a position in ABUS in Q1 2015 and held it in 7 quarters. The position peaked at $2.46M in Q2 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q4 2016.

Suffolk Capital Management reported no remaining Arbutus Biopharma position as of Q4 2016 after selling out during the quarter.
Suffolk Capital Management sold 314,993 Arbutus Biopharma shares in Q4 2016, an estimated $1.08M.
Suffolk Capital Management first reported a position in Arbutus Biopharma in Q1 2015 and held it in 7 quarters.
Suffolk Capital Management's Arbutus Biopharma position peaked at $2.46M in Q2 2015.
55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2016.

Based on Suffolk Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.